Presentations Highlight Data from Phase 1 Study with ACHN-490 and In Vitro Activity of ACHN-490 Against Resistant Bacterial Pathogens and in Combination with Existing Antibiotics
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Achaogen, a biopharmaceutical company discovering and developing antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced key upcoming data presentations involving its lead antibiotic candidate ACHN-490. The data are being presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston from September 12th through September 15th, 2010.
In addition to the poster presentations, on Monday, September 15th from 9:00 am to 9:30 am, George H. Miller, Ph.D., research fellow at Achaogen, will be presenting “Aminoglycosides: Past, Present and Future” as part of the Symposium: “Antibiotic Drug Discovery: How Far Have We Come in 50 Years?”
Following the meeting, full versions of the posters will be available on the Achaogen website at www.achaogen.com.
Achaogen’s most advanced compound, ACHN-490, has been chemically engineered to retain activity against bacteria resistant to carbapenems, cephalosporins, fluoroquinolones, tetracyclines, and legacy aminoglycosides. The compound has demonstrated bactericidal activity in vitro and efficacy in preclinical studies against systemic infections caused by MDR Gram-negative bacteria (e.g., K. pneumoniae, E. coli, and P. aeruginosa) and MRSA. ACHN-490 Injection is currently being investigated in a randomized, double-blind, comparator-controlled Phase 2 clinical study for the treatment of complicated urinary tract infection (cUTI), the most commonly treated hospital infections in the U.S., and acute pyelonephritis.
Achaogen is a biopharmaceutical company focused on the discovery and development of antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today intended to combat tomorrow’s resistant pathogens. Achaogen has established specialized capabilities that have enabled the company to pursue multiple discovery and development programs, and has funded its growth with an innovative blend of private investments and non-dilutive funding from partnerships with the NIH, BARDA, the United States Department of Defense, and others. For more information, please visit the company’s website at www.achaogen.com.
Ashlea Kosikowski, 910-547-7093
KEYWORDS: United States North America California Massachusetts New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Infectious Diseases Oncology Pharmaceutical